New psoriasis pill enters Mid-Stage trial

NCT ID NCT07158268

Not yet recruiting Disease control Sponsor: Haisco Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tests an oral tablet called HSK47388 in 220 adults with moderate-to-severe plaque psoriasis. Participants take the drug or a placebo once daily for 16 weeks. The main goal is to see if the drug can reduce psoriasis severity by at least 75% compared to placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HSK47388 (oral tablet)

What this could lead to

If successful, this could lead to a new daily pill to control moderate-to-severe plaque psoriasis, reducing skin plaques and improving quality of life.

What could go wrong

This is an early phase 2 trial with only 220 people, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PLAQUE PSORIASIS